Dimethylfumarate in the systemic therapy of psoriasis: pathogenesis, clinical efficacy, safety, and prospects for treatment.

Psoriasis is a chronic immune-mediated inflammatory skin disease that requires systemic therapy in a significant proportion of patients. Traditional systemic drugs, including methotrexate, cyclosporine, and acitretin, have proven efficacy, but their use may be limited by the development of toxic effects. In recent years, dimethyl fumarate (DMF), an oral immunomodulatory drug belonging to the fumaric acid ester group with anti-inflammatory and antioxidant properties, has received particular attention. Results from randomized clinical trials and real-world clinical practice demonstrate the efficacy of DMF in the treatment of moderate psoriasis, as well as a favorable safety profile with long-term use. In 2025, a drug based on dimethyl fumarate was registered for the first time in the Russian Federation under the trade name Neptimo® (30 mg and 120 mg). This literature review summarizes current data on the mechanisms of pathogenesis of dimethyl fumarate in psoriasis, its clinical efficacy and safety profile in the treatment of this disease.